Dyne Therapeutics (DYN) Common Equity (2019 - 2026)

Dyne Therapeutics (DYN) has 8 years of Common Equity data on file, last reported at $865.1 million in Q1 2026.

• On a quarterly basis, Common Equity rose 29.31% year-over-year to $865.1 million in Q1 2026; TTM through Mar 2026 was $865.1 million, a 29.31% increase from a year earlier, with the FY2025 full-year figure at $972.1 million, up 54.35% from the prior year.
• Common Equity for Q1 2026 stood at $865.1 million, down from $972.1 million in the prior quarter.
• Over the last five years, Common Equity for DYN reached as high as $972.1 million in Q4 2025 and fell as low as $91.3 million in Q4 2023.
• Historically, Common Equity has averaged $480.9 million across 5 years, with a median of $478.1 million in 2024.
• Across the five-year window, Common Equity plunged 63.83% in 2023 and surged 589.92% in 2024, its largest moves.
• Year by year, Common Equity stood at $252.4 million in 2022, then plunged by 63.83% to $91.3 million in 2023, then jumped by 589.92% to $629.8 million in 2024, then soared by 54.35% to $972.1 million in 2025, then dropped by 11.01% to $865.1 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $865.1 million in Q1 2026, $972.1 million in Q4 2025, and $691.8 million in Q3 2025.